Caris Life Sciences director plans $12.1M sale

Caris Life Sciences, Inc. (CAI) received a Rule 144 notice that director Brian J. Brille plans to sell up to 400,000 shares of common stock through Morgan Stanley Smith Barney LLC.

Available on EDGAR 09/17/2026 - 04:35 PM EDT Accepted by SEC EDGAR 09/17/2026 - 04:34 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Caris Life Sciences, Inc. (CAI) received a Rule 144 notice that director Brian J. Brille plans to sell up to 400,000 shares of common stock through Morgan Stanley Smith Barney LLC. The shares relate to an exercise of options under a registered plan, with an aggregate market value of $12,132,080 and 282,595,000 shares outstanding as of the notice, with an approximate sale date of September 17, 2026.

Key Figures

Shares to be sold: 400,000 shares Aggregate market value: $12,132,080 Shares outstanding: 282,595,000 shares +2 more

5 metrics

Shares to be sold 400,000 shares Common stock covered by the Rule 144 notice

Aggregate market value $12,132,080 Aggregate market value of the 400,000 shares to be sold

Shares outstanding 282,595,000 shares Common shares outstanding as listed in the Form 144 table

Approximate sale date September 17, 2026 Approximate date of sale for the planned disposition

Shares acquired via option exercise 400,000 shares Securities to be sold acquired by exercise of options under a registered plan

Key Terms

Rule 144, Aggregate market value, Exercise of Options Under a Registered Plan, Securities to be sold

4 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Aggregate market value financial

"400000 | 12132080.00 | 282595000 | 09/17/2026 | NASDAQ"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

Exercise of Options Under a Registered Plan financial

"Exercise of Options Under a Registered Plan | Issuer"

Securities to be sold financial

"144: Securities To Be Sold"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing disclose for Caris Life Sciences (CAI)?

It discloses that director Brian J. Brille filed a Rule 144 notice to sell up to 400,000 shares of Caris Life Sciences common stock through Morgan Stanley Smith Barney LLC, related to an exercise of options under a registered plan, with an approximate sale date of September 17, 2026.

How many Caris Life Sciences (CAI) shares are planned to be sold and at what value?

The notice covers up to 400,000 shares of Caris Life Sciences common stock, with an aggregate market value of $12,132,080 stated in the filing.

Who is selling Caris Life Sciences (CAI) shares under this Form 144?

The person for whose account the securities are to be sold is Brian J. Brille, identified as a director, using Morgan Stanley Smith Barney LLC Executive Financial Services as the broker.

When are the Caris Life Sciences (CAI) shares expected to be sold under this notice?

The filing lists an approximate date of sale of September 17, 2026 for the planned sale of Caris Life Sciences common stock under Rule 144.

How many Caris Life Sciences (CAI) shares are outstanding in this Form 144?

The Form 144 reports 282,595,000 shares of Caris Life Sciences common stock outstanding in the same table that lists the planned sale of 400,000 shares.

How were the Caris Life Sciences (CAI) shares to be sold acquired?

The securities to be sold are reported as acquired through an “Exercise of Options Under a Registered Plan”, with the filing stating a cash nature of payment and an acquisition date of September 17, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0002071959
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	CARIS LIFE SCIENCES, INC.
SEC File Number	001-42706
Address of Issuer	750 W JOHN CARPENTER FREEWAY SUITE 800 IRVING TEXAS 75039
Phone	(866) 771-8946
Name of Person for Whose Account the Securities are To Be Sold	BRIAN J BRILLE
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	400000	12132080.00	282595000	09/17/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	09/17/2026	Exercise of Options Under a Registered Plan	Issuer			400000	09/17/2026	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	09/17/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Brian J Brille
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)